| Stereochemistry | UNKNOWN |
| Molecular Formula | C15H22N2O6 |
| Molecular Weight | 326.345 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)COC1=C2OCC(CC2=CC=C1)O[N+]([O-])=O
InChI
InChIKey=OMCPLEZZPVJJIS-UHFFFAOYSA-N
InChI=1S/C15H22N2O6/c1-10(2)16-7-12(18)8-21-14-5-3-4-11-6-13(23-17(19)20)9-22-15(11)14/h3-5,10,12-13,16,18H,6-9H2,1-2H3
| Molecular Formula | C15H22N2O6 |
| Molecular Weight | 326.345 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Nipradilol is a beta blocker and nitric oxide donor. It was launched in Japan in 1988. This medicine lowers intraocular pressure by suppressing aqueous production and increasing fluid drainage from the eye. It is usually used to treat glaucoma and intraocular hypertension. The most commonly reported adverse reactions include conjunctival congestion, superficial keratitis, eye irritation, bloodshot eyes, itch and headache. If any of these symptoms occur, consult with your doctor or pharmacist.
